Jason Rhodes

Jason Rhodes is a Partner at Atlas Venture and focuses on creating and building novel therapeutics companies. Jason is the Executive Chair of the Board of Rectify. Jason was the founding CEO of Generation Bio and Dyne Therapeutics. He is also on the boards of Replimune, Accent Therapeutics, and Be Biopharma. He was the chair and founding CEO of Disarm Therapeutics, acquired by Eli Lilly. Previously, Jason held leadership positions at Epizyme, where he was President and built the company from early-stage research into the clinic and through a successful IPO, and at Alnylam Pharmaceuticals, where he led business development. Jason was also a founder and partner with Fidelity Biosciences (now F-Prime Capital), the life sciences venture capital arm of Fidelity Investments, where he led investments in therapeutics companies including FoldRx, acquired by Pfizer. He is a member of the advisory board of the Harvard Institute for RNA Medicine, the Blavatnik Fund at Yale University, and the Berklee College of Music Presidential Advisory Council. Jason received his B.A. from Yale University and his M.B.A. from the Wharton School of the University of Pennsylvania.